Over time, myelofibrosis (MF) can affect the way your body makes the three types of blood cells: red, white, and platelets. That can cause symptoms or illnesses. Both men and women can get it ...

Tania Jain, MBBS: Welcome everyone. We are in season 2 of myelofibrosis for the Medscape InDiscussion podcast. I'm your host, Tania Jain. Today we will discuss endpoints for myelofibrosis clinical ...

A machine learning model generated by a team from the European Society for Blood and Marrow Transplantation (EBMT) ...

Pelabresib, a bromodomain and extraterminal domain inhibitor, plus ruxolitinib (a Janus kinase [JAK] inhibitor) improves ...

Nearly all myelofibrosis patients globally are estimated to develop anaemia over the course of the disease, and over 30% will ...

Dr. Raajit Rampal studies myelofibrosis in the lab and in the clinic. An international phase 3 clinical trial of a new drug combination for treating the blood cancer myelofibrosis found that adding a ...

They may include: About 10% to 15% of the time, polycythemia vera changes into myelofibrosis. This is called post-polycythemia vera myelofibrosis. Myelofibrosis is a blood cancer where your bone ...

CALR mutations occur in about 20% of patients with primary and post-essential thrombocythemia myelofibrosis, as per the study ...

In this video, John O. Mascarenhas, MD, professor of medicine at the Icahn School of Medicine, discussed recent developments and emerging treatments in myeloproliferative neoplasms care.

In this video, John O. Mascarenhas, MD, professor of medicine at the Icahn School of Medicine, discussed recent developments and emerging treatments in myeloproliferative neoplasms care.